ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Stopped early

Conditions studied: Pain Resulting From Bone Metastases

In brief

The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.

Key facts

Study ID

NCT01834937

Run by

InSightec

People needed

17

Starts

2013-06-01

Expected to finish

2017-04-01

Last updated by the study team

2018-11-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States
• University of California San Francisco — San Francisco, California, United States
• Stanford University — Stanford, California, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Weill Cornell Medical Center — New York, New York, United States
• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.